PCSK9 and hemophilia: These nanocarriers were shown to be safe and efficient LNPs for hemophilia therapy via CRISPR–Cas9‐mediated genome editing.[48] A research group also developed LNPs for the codelivery of enhanced sgRNA against proprotein convertase subtilisin/kexin type 9 (Pcsk9) and Cas9 mRNA in the liver to attain >80% editing of Pcsk9, with serum Pcsk9 reduced to undetectable levels and cholesterol levels found to be significantly lowered in vivo.